Evidence map›Paper›PMID 21886829›Full record

ArticlePloS one2011

Metastasis of tumor cells is enhanced by downregulation of Bit1.

Priya Prakash Karmali, Chris Brunquell, Hau Tram, Shubha Kale Ireland, Erkki Ruoslahti, Hector Biliran

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Bit1-a potential positive regulator of epithelial-mesenchymal transition in lens epithelial cells.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2016
    Article
  12. Article
  13. Review
  14. Article
  15. Implications of Bit1 and AIF overexpressions in esophageal squamous cell carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Priya Prakash KarmaliSanford-Burnham Medical Research Institute, La Jolla, California, United States of America.
Chris Brunquell
Hau Tram
Shubha Kale Ireland
Erkki Ruoslahti
Hector Biliran
Sanford Burnham Prebys Medical Discovery Institute · USXavier University of Louisiana · US

Funding

Specific Targets for Pancreatic Cancer TherapyR01CA109389 · NCI · WAYNE STATE UNIVERSITY · PI MOHAMMAD, RAMZI M. · 2007 to 2011
$1.2M
NCI NIH HHS R01 CA109389
6 · The paper itself

Abstract

backgroundResistance to anoikis, which is defined as apoptosis induced by loss of integrin-mediated cell attachment to the extracellular matrix, is a determinant of tumor progression and metastasis. We have previously identified the mitochondrial Bit1 (Bcl-2 inhibitor of transcription) protein as a novel anoikis effector whose apoptotic function is independent from caspases and is uniquely controlled by integrins. In this report, we examined the possibility that Bit1 is suppressed during tumor progression and that Bit1 downregulation may play a role in tumor metastasis. METHODOLOGY/PRINCIPAL

findingsUsing a human breast tumor tissue array, we found that Bit1 expression is suppressed in a significant fraction of advanced stages of breast cancer. Targeted disruption of Bit1 via shRNA technology in lowly aggressive MCF7 cells conferred enhanced anoikis resistance, adhesive and migratory potential, which correlated with an increase in active Extracellular kinase regulated (Erk) levels and a decrease in Erk-directed phosphatase activity. These pro-metastasis phenotypes were also observed following downregulation of endogenous Bit1 in Hela and B16F1 cancer cell lines. The enhanced migratory and adhesive potential of Bit1 knockdown cells is in part dependent on their high level of Erk activation since down-regulating Erk in these cells attenuated their enhanced motility and adhesive properties. The Bit1 knockdown pools also showed a statistically highly significant increase in experimental lung metastasis, with no differences in tumor growth relative to control clones in vivo using a BALB/c nude mouse model system. Importantly, the pulmonary metastases of Bit1 knockdown cells exhibited increased phospho-Erk staining. CONCLUSIONS/SIGNIFICANCE: These findings indicate that downregulation of Bit1 conferred cancer cells with enhanced anoikis resistance, adhesive and migratory properties in vitro and specifically potentiated tumor metastasis in vivo. These results underscore the therapeutic importance of restoring Bit1 expression in cancer cells to circumvent metastasis at least in part through inhibition of the Erk pathway.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsAnoikisBreast NeoplasmsCarboxylic Ester HydrolasesCell Line, TumorDisease ProgressionDown-RegulationFemaleHumansLung NeoplasmsMAP Kinase Signaling SystemMiceMice, Inbred BALB CNeoplasm MetastasisNeoplasmsCarboxylic Ester HydrolasesPtrh2 protein, mouse

Identifiers

PMID21886829
PMCPMC3160313
OpenAlexW2009983088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.